Literature DB >> 11598017

The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element.

T O Tange1, C K Damgaard, S Guth, J Valcárcel, J Kjems.   

Abstract

The generation of >30 different HIV-1 mRNAs is achieved by alternative splicing of one primary transcript. The removal of the second tat intron is regulated by a combination of a suboptimal 3' splice site and cis-acting splicing enhancers and silencers. Here we show that hnRNP A1 inhibits splicing of this intron via a novel heterogeneous nuclear ribonucleoprotein (hnRNP) A1-responsive intron splicing silencer (ISS) that can function independently of the previously characterized exon splicing silencer (ESS3). Surprisingly, depletion of hnRNP A1 from the nuclear extract (NE) enables splicing to proceed in NE that contains 100-fold reduced concentrations of U2AF and normal levels of SR proteins, conditions that do not support processing of other efficiently spliced pre-mRNAs. Reconstituting the extract with recombinant hnRNP A1 protein restores splicing inhibition at a step subsequent to U2AF binding, mainly at the time of U2 snRNP association. hnRNP A1 interacts specifically with the ISS sequence, which overlaps with one of three alternative branch point sequences, pointing to a model where the entry of U2 snRNP is physically blocked by hnRNP A1 binding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598017      PMCID: PMC125679          DOI: 10.1093/emboj/20.20.5748

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

1.  Intron recognition comes of AGe.

Authors:  M J Moore
Journal:  Nat Struct Biol       Date:  2000-01

2.  The spliceosome assembly pathway in mammalian extracts.

Authors:  S F Jamison; A Crow; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

3.  General splicing factors SF2 and SC35 have equivalent activities in vitro, and both affect alternative 5' and 3' splice site selection.

Authors:  X D Fu; A Mayeda; T Maniatis; A R Krainer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

4.  Primary structure of the human splicing factor ASF reveals similarities with Drosophila regulators.

Authors:  H Ge; P Zuo; J L Manley
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

5.  Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor.

Authors:  P D Zamore; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

6.  The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA.

Authors:  J Valcárcel; R Singh; P D Zamore; M R Green
Journal:  Nature       Date:  1993-03-11       Impact factor: 49.962

7.  Specific commitment of different pre-mRNAs to splicing by single SR proteins.

Authors:  X D Fu
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

8.  Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF.

Authors:  A Mayeda; D M Helfman; A R Krainer
Journal:  Mol Cell Biol       Date:  1993-05       Impact factor: 4.272

9.  Intronic sequences and 3' splice sites control Rous sarcoma virus RNA splicing.

Authors:  M T McNally; K Beemon
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

10.  The role of exon sequences in splice site selection.

Authors:  A Watakabe; K Tanaka; Y Shimura
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

View more
  69 in total

1.  Decrease in hnRNP A/B expression during erythropoiesis mediates a pre-mRNA splicing switch.

Authors:  Victor C Hou; Robert Lersch; Sherry L Gee; Julie L Ponthier; Annie J Lo; Michael Wu; Chris W Turck; Mark Koury; Adrian R Krainer; Akila Mayeda; John G Conboy
Journal:  EMBO J       Date:  2002-11-15       Impact factor: 11.598

2.  A novel function for Sam68: enhancement of HIV-1 RNA 3' end processing.

Authors:  Meredith McLaren; Kengo Asai; Alan Cochrane
Journal:  RNA       Date:  2004-07       Impact factor: 4.942

3.  Genomic mRNA profiling reveals compensatory mechanisms for the requirement of the essential splicing factor U2AF.

Authors:  Vinod Sridharan; Joseph Heimiller; Ravinder Singh
Journal:  Mol Cell Biol       Date:  2010-12-13       Impact factor: 4.272

Review 4.  Diverse regulation of 3' splice site usage.

Authors:  Muhammad Sohail; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2015-09-14       Impact factor: 9.261

5.  ELAV multimerizes on conserved AU4-6 motifs important for ewg splicing regulation.

Authors:  Matthias Soller; Kalpana White
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  New way of regulating alternative splicing in retroviruses: the promoter makes a difference.

Authors:  Jens Bohne; Axel Schambach; Daniela Zychlinski
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

Review 7.  Idiosyncrasies of hnRNP A1-RNA recognition: Can binding mode influence function.

Authors:  Jeffrey D Levengood; Blanton S Tolbert
Journal:  Semin Cell Dev Biol       Date:  2018-04-09       Impact factor: 7.727

8.  The First Crystal Structure of the UP1 Domain of hnRNP A1 Bound to RNA Reveals a New Look for an Old RNA Binding Protein.

Authors:  Christopher E Morgan; Jennifer L Meagher; Jeffrey D Levengood; James Delproposto; Carrie Rollins; Jeanne A Stuckey; Blanton S Tolbert
Journal:  J Mol Biol       Date:  2015-05-21       Impact factor: 5.469

Review 9.  Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches.

Authors:  Mo Chen; James L Manley
Journal:  Nat Rev Mol Cell Biol       Date:  2009-09-23       Impact factor: 94.444

10.  Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1.

Authors:  Jeffrey H Ringrose; Rienk E Jeeninga; Ben Berkhout; Dave Speijer
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.